InflaMix Identifies CAR-T Recipients with a Preinfusion Inflammatory Profile Indicative of High Risk for CAR-T Treatment Failure By Ogkologos - May 5, 2025 265 0 Facebook Twitter Google+ Pinterest WhatsApp A valuable tool for point-of-care clinical decision-making in patients with non-Hodgkin lymphoma Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR What People With Cancer Should Know About Immune Checkpoint Inhibitor Side... November 1, 2021 ΙΣΤΟΡΙΑ January 18, 2019 Alcohol Tied to 750,000 Cancer Cases Worldwide in 2020 August 12, 2021 GreaterGood Is Donating Thousands of Masks to Help Animal Shelters Stay... September 17, 2020 Load more HOT NEWS Pregnancy is Safe After Early Breast Cancer in Young Women with... EMA Recommends Extension of Indications for Osimertinib Spring Budget 2023: What does it mean for the mission to... ΚΑΡΚΙΝΟΣ ΤΟΥ ΠΡΟΣΤΑΤΗ
